IL210489A0 - Use of hdac inhibitors for the treatment of hodgkin's disease - Google Patents

Use of hdac inhibitors for the treatment of hodgkin's disease

Info

Publication number
IL210489A0
IL210489A0 IL210489A IL21048911A IL210489A0 IL 210489 A0 IL210489 A0 IL 210489A0 IL 210489 A IL210489 A IL 210489A IL 21048911 A IL21048911 A IL 21048911A IL 210489 A0 IL210489 A0 IL 210489A0
Authority
IL
Israel
Prior art keywords
hodgkin
disease
treatment
hdac inhibitors
hdac
Prior art date
Application number
IL210489A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL210489A0 publication Critical patent/IL210489A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL210489A 2008-07-18 2011-01-06 Use of hdac inhibitors for the treatment of hodgkin's disease IL210489A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8180508P 2008-07-18 2008-07-18
PCT/US2009/050768 WO2010009280A1 (en) 2008-07-18 2009-07-16 Use of hdac inhibitors for the treatment of hodgkin's disease

Publications (1)

Publication Number Publication Date
IL210489A0 true IL210489A0 (en) 2011-03-31

Family

ID=41128203

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210489A IL210489A0 (en) 2008-07-18 2011-01-06 Use of hdac inhibitors for the treatment of hodgkin's disease

Country Status (15)

Country Link
US (1) US20110118309A1 (enExample)
EP (1) EP2306996A1 (enExample)
JP (1) JP2011528662A (enExample)
KR (1) KR20110031980A (enExample)
CN (1) CN102099021A (enExample)
AU (1) AU2009270886A1 (enExample)
BR (1) BRPI0915927A2 (enExample)
CA (1) CA2730738A1 (enExample)
CL (1) CL2011000100A1 (enExample)
IL (1) IL210489A0 (enExample)
MA (1) MA32482B1 (enExample)
MX (1) MX2011000719A (enExample)
TW (1) TW201006470A (enExample)
WO (1) WO2010009280A1 (enExample)
ZA (1) ZA201100165B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102020939B1 (ko) * 2011-07-07 2019-09-11 리서치 캔서 인스티튜트 오브 아메리카 암 치료 시스템, 방법 및 제형
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11369585B2 (en) 2017-03-17 2022-06-28 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
EP3710434A4 (en) 2017-11-17 2021-07-28 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
US20220387604A1 (en) * 2019-11-06 2022-12-08 Dana-Farber Cancer Institute, Inc. Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2009541488A (ja) * 2006-06-26 2009-11-26 ノバルティス アクチエンゲゼルシャフト 有機化合物
US8093220B2 (en) * 2006-12-04 2012-01-10 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite

Also Published As

Publication number Publication date
CN102099021A (zh) 2011-06-15
CL2011000100A1 (es) 2011-07-01
JP2011528662A (ja) 2011-11-24
WO2010009280A1 (en) 2010-01-21
AU2009270886A1 (en) 2010-01-21
TW201006470A (en) 2010-02-16
ZA201100165B (en) 2011-09-28
US20110118309A1 (en) 2011-05-19
MX2011000719A (es) 2011-03-01
KR20110031980A (ko) 2011-03-29
EP2306996A1 (en) 2011-04-13
MA32482B1 (fr) 2011-07-03
BRPI0915927A2 (pt) 2016-06-07
CA2730738A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
IL210261A0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0914450A2 (pt) "equipamento de estrumental círurgico"
GB0908173D0 (en) Process for facilitating the management of care
ZA201101303B (en) Kit for the treatment of onychomycosis
LT2427193T (lt) Pde7 inhibitoriaus panaudojimas judėjimo sutrikimų gydymui
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
SI1912640T1 (sl) Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
HK1155099A (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma
ITMI20080223A1 (it) Apparato per l'applicazione di trattamenti di ipertermia